Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Research & Development (2016 - 2025)

Haemonetics has reported Research & Development over the past 17 years, most recently at $14.2 million for Q4 2025.

  • Quarterly results put Research & Development at $14.2 million for Q4 2025, down 10.37% from a year ago — trailing twelve months through Dec 2025 was $63.6 million (up 5.56% YoY), and the annual figure for FY2025 was $62.7 million, up 15.22%.
  • Research & Development for Q4 2025 was $14.2 million at Haemonetics, down from $14.9 million in the prior quarter.
  • Over the last five years, Research & Development for HAE hit a ceiling of $18.3 million in Q1 2025 and a floor of $10.0 million in Q1 2022.
  • Median Research & Development over the past 5 years was $13.2 million (2022), compared with a mean of $13.5 million.
  • Biggest five-year swings in Research & Development: soared 63.88% in 2021 and later dropped 14.16% in 2022.
  • Haemonetics' Research & Development stood at $10.9 million in 2021, then increased by 16.92% to $12.7 million in 2022, then rose by 4.54% to $13.3 million in 2023, then grew by 19.33% to $15.8 million in 2024, then decreased by 10.37% to $14.2 million in 2025.
  • The last three reported values for Research & Development were $14.2 million (Q4 2025), $14.9 million (Q3 2025), and $16.3 million (Q2 2025) per Business Quant data.